HIND
Vyome Holdings, Inc.
Set alert
1.80 USD +0.07 +4.05%
1.72 Day range 2.14
1.70 52-week range 6.31
- YTD
- -47.67%
- 1 year
- -67.74%
- Open
- 1.73
- Prev close
- 1.73
- Mkt cap
- 12.63M
- Vol
- 42.19K
- Avg vol
- 12.73K
- EPS
- 1.78
- P/E
- 1.01
- Div yield
- 0.00%
More statistics
- Low
- 1.72
- High
- 2.14
Financials — quick view
HIND Revenue — quarterly 26.95K
HIND Net income — quarterly -685.56K
HIND EPS — quarterly -0.09
News
- Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School
- Vyome Receives USPTO Notice of Allowance for U.S. Patent Covering VT-1908, its Novel Topical Mycophenolate Program Targeting the $20+ Billion Ocular Inflammation Market
- Vyome Holdings' ReShape Lifesciences Has Received A Notice Of Allowance For A U.S. Patent Titled "VAGUS NERVE NEUROMODULATION FOR THE TREATMENT OF THE HYPOGLYCEMIC STATE".
- Vyome Holdings Appoints Jerry Leonard As CFO, Succeeding Robert Dickey IV, Who Served As Interim CFO Since August 2025
- Vyome Appoints Experienced Public Company Finance Executive Jerry Leonard as Chief Financial Officer
- Chardan Capital Initiates Coverage On Vyome Holdings with Buy Rating, Announces Price Target of $3.5
- Vyome Appoints Jerry Leonard As CFO On August 27, 2026
- Vyome Holdings Reports Second Quarter 2026 Results Highlighted by Advancement of Lead VT-1953 Program, Pipeline Expansion and Strong Balance Sheet
- 12 Health Care Stocks Moving In Friday's After-Market Session
- China National Intellectual Property Administration Grants Vyome Patent Chinese Patent No. ZL 2021 1 0758695.X
Your note
Sign in to keep a note on HIND — it syncs with the Stock Master app.